ZYMEWORKS INC. - COMMON STOCK

Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results

01 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

30 Jul 2024 05:30:00 By Nasdaq GlobeNewswire

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

25 Jul 2024 15:30:00 By Nasdaq GlobeNewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

22 Jul 2024 05:00:38 By Nasdaq GlobeNewswire

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

11 Jul 2024 05:30:00 By Nasdaq GlobeNewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

17 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

10 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

28 May 2024 05:30:00 By Nasdaq GlobeNewswire

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

02 May 2024 15:05:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

30 Apr 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

11 Apr 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

08 Apr 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

28 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

27 Mar 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

06 Mar 2024 15:09:10 By Nasdaq GlobeNewswire

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

27 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call

14 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

08 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

31 Jan 2024 05:00:00 By Nasdaq GlobeNewswire